Immunology and Genetics Journal
https://publish.kne-publishing.com/index.php/IGJ
<p><strong data-stringify-type="bold">All the manuscripts should be submitted through the Journal Primary Website at <a href="https://igj.tums.ac.ir/index.php/igj/about/submissions">https://igj.tums.ac.ir/index.php/igj/about/submissions</a></strong></p>Tehran University of Medical Sciencesen-USImmunology and Genetics Journal 2645-4831Autoimmunity in Inborn Errors of Immunity: A Diagnostic Challenge Beyond Immunodeficiency
https://publish.kne-publishing.com/index.php/IGJ/article/view/18169
<div id="message-list_1667106617.716519" class="c-virtual_list__item" tabindex="0" role="listitem" aria-setsize="-1" data-qa="virtual-list-item" data-item-key="1667106617.716519"> <div class="c-message_kit__background p-message_pane_message__message c-message_kit__message" role="presentation" data-qa="message_container" data-qa-unprocessed="false" data-qa-placeholder="false"> <div class="c-message_kit__hover" role="document" aria-roledescription="message" data-qa-hover="true"> <div class="c-message_kit__actions c-message_kit__actions--above"> <div class="c-message_kit__gutter"> <div class="c-message_kit__gutter__right" role="presentation" data-qa="message_content"> <div class="c-message_kit__blocks c-message_kit__blocks--rich_text"> <div class="c-message__message_blocks c-message__message_blocks--rich_text" data-qa="message-text"> <div class="p-block_kit_renderer" data-qa="block-kit-renderer"> <div class="p-block_kit_renderer__block_wrapper p-block_kit_renderer__block_wrapper--first"> <div class="p-rich_text_block" dir="auto"> <div class="p-rich_text_section">The Article Abstract is not available.</div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> <div id="message-list_1669062600000divider" class="c-virtual_list__item" tabindex="-1" role="presentation" aria-setsize="-1" data-qa="virtual-list-item" data-item-key="1669062600000divider"> <div class="c-message_list__day_divider" data-stringify-ignore="true"> </div> </div>Reza Yazdani
Copyright (c) 2025 Immunology and Genetics Journal
2025-03-152025-03-1510.18502/igj.v8i3.18169National Consensus Guideline on Diagnosis and Management of Chronic Granulomatous Disease
https://publish.kne-publishing.com/index.php/IGJ/article/view/18170
<div class="page" title="Page 2"> <div class="section"> <div class="layoutArea"> <div class="column"> <p>Currently, a national consensus or guideline for diagnosing and managing patients suspected of having chronic granulomatous disease (CGD) is lacking. This consensus is written based on a combination of scien- tific literature and comments from the expert panel of Iranian immunologists. A group of clinical immunol- ogists reviewed the current consensus, presented their comments at a meeting titled “First Meeting on the Diagnosis of Inborn Errors of Immunity (IEI) by IEI Experts” and agreed on this consensus. This consensus guideline provides recommendations on the diagnosis, antimicrobial prophylaxis, management of clinical manifestations, administration of interferon gamma (IFN-γ) and hematopoietic stem cell transplantation (HSCT) for patients with CGD.</p> </div> </div> </div> </div>Samaneh DelavariReza YazdaniHassan AbolhassaniFereshte SalamiParisa AshourniaAida AskarisarvestaniSima BahramiMaryam BehfarMohammad Hassan BemanianTaher CheraghiKian DarabiSepideh DarougarSarehsadat EbrahimiEbrahimiShabnam EskandarzadehGolnaz EslamianNarges EslamiShahrzad FallahMorteza FallahpourSaba FekrvandAli HaghbinZohre HassanpoorTolue MahdaviHoma Hatefi MinaeiMajid MarjaniShahla MiraziziMohammadreza ModaresiMahshid MovahediMohammamd NabaviMojtaba RanjbarAnahita RazaghianMohammad SaberiMahnaz Sadeghi-ShabestariMitra SahragardKiarash SalekiSahar SerajSeyedehshabnam SeyedsalehiAlireza ShafieiRoya SherkatReza ShiariSima ShokriSaman TavakoliAhmad VosughimotlaghNima Rezaei
Copyright (c) 2025 Immunology and Genetics Journal
2025-03-162025-03-1610.18502/igj.v8i3.18170National Consensus Guideline on Diagnosis and Management of Congenital Neutropenias
https://publish.kne-publishing.com/index.php/IGJ/article/view/18171
<div class="page" title="Page 2"> <div class="section"> <div class="layoutArea"> <div class="column"> <p>At present, a national consensus or guideline for diagnosing and managing patients suspected of having se- vere congenital neutropenia (SCN) is lacking. This consensus is written based on a combination of scientific literature and comments from the expert panel of Iranian immunologists. A group of clinical immunolo- gists reviewed the current consensus, presented their comments at a meeting titled “First Meeting on the Diagnosis of Inborn Errors of Immunity (IEI) by IEI Experts” and agreed on this consensus. This consensus guideline provides recommendations on the diagnosis, antimicrobial prophylaxis, management of clinical manifestations, administration of granulocyte colony-stimulating factor (G-CSF) and hematopoietic stem cell transplantation (HSCT) for patients with SCN.</p> </div> </div> </div> </div>Saba FekrvandReza YazdaniSamaneh AbdolahzadeParisa AshourniaAida AskarisarvestaniSima BahramiMaryam BehfarZahra DaneshmandiTaher CheraghiSepideh DarougarSarehsadat EbrahimiShabnam EskandarzadehNarges EslamiGolnaz EslamianShahrzad FallahAli HaghbinMehrnaz MesdaghiMajid MarjaniMohammadreza Modaresi Mahshid MovahediMohammamd NabaviAnahita RazaghianMahnaz Sadeghi-ShabestariSahar SerajSeyedehshabnam SeyedsalehiAlireza ShafieiReza Shiari Sima ShokriSaman TavakoliAhmad VosughimotlaghVahid ZiaeeNima Rezaei
Copyright (c) 2025 Immunology and Genetics Journal
2025-03-162025-03-1610.18502/igj.v8i3.18171Tumor Markers Involved in Invasion of Pancreatic Cancer
https://publish.kne-publishing.com/index.php/IGJ/article/view/18208
<div class="page" title="Page 1"> <div class="section"> <div class="layoutArea"> <div class="column"> <p>Pancreatic cancer is still one of the most lethal malignancies across the world, and hence exploring new bio- markers related to the progression and invasive nature of this cancer is important to overcome its resistance to various types of treatments through the design of new therapeutic strategies. Several markers have been shown to play a role in pancreatic cancer invasion, but CA19-9, CA125, and noncoding RNAs, including microRNAs, long noncoding RNAs, and circular RNAs, are the most common ones. In the current review, the role of these markers in pancreatic cancer progression, invasion, and metastasis, as well as related mech- anisms, has been provided, and their potential to be utilized in pancreatic cancer diagnosis and treatment has been discussed.</p> </div> </div> </div> </div>Fatemeh TajikSara Kamali ZonouziSepideh Razi
Copyright (c) 2025 Immunology and Genetics Journal
2025-03-162025-03-1610.18502/igj.v8i3.18208Regional Distribution of Ataxia-Telangiectasia Cases in Iran
https://publish.kne-publishing.com/index.php/IGJ/article/view/18209
<div class="page" title="Page 1"> <div class="section"> <div class="layoutArea"> <div class="column"> <p><strong>Background:</strong> Ataxia-telangiectasia (AT) is a rare, autosomal recessive neurodegenerative disease charac- terized by progressive cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, recurrent infec- tions, radiosensitivity, and an increased risk of malignancies. This study aimed to evaluate the distribution of A-T patients, parenteral consanguinity status, and diagnostic delays in different provinces of Iran.</p> <p><strong>Methods:</strong> A retrospective observational and analytical study in which all A-T patients with a recorded place of birth or residency were included. A questionnaire was designed and filled out for each patient to extract data including date of birth, gender, parental consanguinity status, family history, age of disease onset, and age of disease diagnosis.</p> <p><strong>Results:</strong> A total of 203 A-T patients (104 males and 99 females) were included in the study. Out of a total of 31 provinces, A-T patients were diagnosed and reported in 25 different provinces, while six provinces had no registered A-T patients. Tehran province, the most densely populated province in Iran, reported the pre- dominant number and frequency of cases (52 patients or 25.6%), followed by Khouzestan (16 cases, 7.9%), Alborz (12 cases, 5.9%) and Isfahan (12 cases, 5.9%) provinces. No statistically significant relationship was found regarding family history status. Hamedan followed by Sistan and Baluchestan, and Yazd provinces had the highest delay in diagnosis.</p> <p><strong>Conclusion:</strong> Our study showed that A-T is distributed in most provinces of Iran. We found a considera- bly high diagnostic delay among A-T patients in Iran, especially in resource-limited provinces, including Hamedan followed by Sistan and Baluchestan, and Yazd.</p> <p> </p> </div> </div> </div> </div>Pouya VakilipourAyda FirouzabadiNima RezaeiReza Yazdani
Copyright (c) 2025 Immunology and Genetics Journal
2025-03-162025-03-1610.18502/igj.v8i3.18209 Congenital Cardiac Defects in G6PC3 Deficiency: Report of a Mutation and a Literature Review
https://publish.kne-publishing.com/index.php/IGJ/article/view/18211
<div class="page" title="Page 1"> <div class="section"> <div class="layoutArea"> <div class="column"> <p>Congenital cardiac anomalies are considered the most frequent non-hematologic manifestation of Glucose- 6-phosphatase 3 (G6PC3) deficiency. We report a case of G6PC3-deficiency with a novel homozygous frameshift variant (c.911dupC; p.Gln305SerfsTer82), who developed intermittent neutropenia and was diagnosed long after a repair cardiac surgery for patent ductus arteriosus (PDA). To further investigate the importance of immunologic workups in patients with congenital cardiac defects, we provide a literature review on the observed cardiac findings in patients with SCN4. Overall, 78.3% of reported patients had cardiac defects, with more than half of the patients (56%) presenting with ASD. More than half of the patients with ASD required surgical repair, which implies the severity of symptoms. These findings highlight the importance of performing immunologic work-ups in children initially manifesting congenital heart defects. A simple differential cell-blood-count test may prevent future life-threatening disseminated infections, especially in countries with high rates of consanguinity and, subsequently, higher prevalence of primary immunodeficiencies.</p> </div> </div> </div> </div>Mahsima ShabaniElham RayzanIdo SomekhChristoph KleinNima Rezaei
Copyright (c) 2025 Immunology and Genetics Journal
2025-03-162025-03-1610.18502/igj.v8i3.18211 De novo CXCR4 Mutation in WHIM Syndrome: Report of a 4-year- old Case Without Wart and Myelokathexis
https://publish.kne-publishing.com/index.php/IGJ/article/view/18212
<div class="page" title="Page 1"> <div class="section"> <div class="layoutArea"> <div class="column"> <p>WHIM syndrome ( Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis syndrome), a type of severe congenital neutropenia (SCN), involves Warts, Hypogammaglobulinemia, Infections, and Myelokathexis as its main components of clinical presentation, which results from mutations in the C-X-C chemokine receptor type 4 (CXCR4) gene.</p> <p>Here, we present an Iranian 4-year-old girl with severe congenital neutropenia without warts and normal bone marrow examination, lacking evidence of myelokathexis. Whole Exome Sequencing (WES) was performed for the patient. Subsequently, Sanger segregation/validation was done of the patient and her parents. Whole exam sequencing identified a heterozygous stop variant mutation in CXCR4 (NM_001008540.2:c.1012C>T; p.Arg338Ter) in the patient. Two of the main clinical criteria in WHIM syndrome, including warts and myelokathexis, were not observed in our patient. So, the absence of warts is not deceptive in ruling out the disease. This case report also represents the high importance of genetic analysis as a primary tool for the accurate differential diagnosis of patients with neutropenia.</p> </div> </div> </div> </div>Shayan RoshdiSepideh Shahkarami Samaneh ZoghiElham RayzanRasol MolatefiMeino RohlfChristoph KleinNima Rezaei
Copyright (c) 2025 Immunology and Genetics Journal
2025-03-162025-03-1610.18502/igj.v8i3.18212